Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.35 -6.2%	$14.44	$6.66 ▼ $17.15	$345.46M	0.44	45,937 shs	199,226 shs
ERAS Erasca	$1.26 -8.7%	$1.38	$1.01 ▼ $3.45	$390.94M	1.09	1.73 million shs	1.27 million shs
ITOS iTeos Therapeutics	$10.02 -0.2%	$8.63	$4.80 ▼ $18.13	$384.27M	1.51	684,340 shs	1.03 million shs
OPTN OptiNose	$9.60	$9.49	$4.82 ▼ $19.50	$97.22M	-0.88	65,124 shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-6.16%	-17.34%	-13.76%	-8.04%	+84.05%
ERAS Erasca	-8.70%	-10.00%	+16.67%	-17.11%	-42.73%
ITOS iTeos Therapeutics	-0.20%	+0.20%	+17.47%	+58.54%	-33.38%
OPTN OptiNose	0.00%	0.00%	0.00%	+4.92%	-35.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.4412 of 5 stars	3.6	2.0	0.0	2.7	2.5	0.0
ERAS Erasca	2.829 of 5 stars	3.5	0.0	0.0	3.8	2.5	1.3
ITOS iTeos Therapeutics	3.7339 of 5 stars	4.1	4.0	0.0	2.2	3.3	0.6
OPTN OptiNose	0.652 of 5 stars	1.0	0.0	4.2	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.22	Buy	$23.83	92.98% Upside
ERAS Erasca	3.00	Buy	$4.57	262.81% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	58.25% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside

Current Analyst Ratings Breakdown

Latest OPTN, ERAS, BNTC, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	4,052.34	N/A	N/A	$4.68 per share	2.64
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
ITOS iTeos Therapeutics	$35M	10.96	N/A	N/A	$16.16 per share	0.62
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	N/A
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)

Latest OPTN, ERAS, BNTC, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
ERAS Erasca	N/A	12.35	12.35
ITOS iTeos Therapeutics	N/A	14.13	14.13
OPTN OptiNose	N/A	0.79	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
ERAS Erasca	67.78%
ITOS iTeos Therapeutics	97.16%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
ERAS Erasca	14.40%
ITOS iTeos Therapeutics	12.50%
OPTN OptiNose	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
ERAS Erasca	120	283.29 million	242.49 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable

OPTN, ERAS, BNTC, and ITOS Headlines

Recent News About These Companies

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21, 2025 | finance.yahoo.com

Optinose Stockholders Approve Merger with Paratek

May 16, 2025 | tipranks.com

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

April 29, 2025 | businesswire.com

Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income

March 28, 2025 | msn.com

Optinose reports Q4 EPS (3c) vs ($1.33) last year

March 27, 2025 | markets.businessinsider.com

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

March 26, 2025 | markets.businessinsider.com

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

March 26, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

March 25, 2025 | morningstar.comM

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

March 24, 2025 | zacks.com

Optinose downgraded to Neutral from Buy at H.C. Wainwright

March 22, 2025 | markets.businessinsider.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

March 21, 2025 | businesswire.com

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

March 21, 2025 | zacks.com

Optinose downgraded to Neutral from Overweight at Piper Sandler

March 21, 2025 | markets.businessinsider.com

Optinose downgraded to Hold from Buy at Lake Street

March 21, 2025 | markets.businessinsider.com

Lake Street Downgrades OptiNose (OPTN)

March 21, 2025 | msn.com

Why OptiNose Inc. (OPTN) Surged On Thursday?

March 21, 2025 | msn.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

March 21, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPTN, ERAS, BNTC, and ITOS Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.35 -0.81 (-6.16%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$12.37 +0.02 (+0.16%)

As of 06/26/2025 04:20 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Erasca NASDAQ:ERAS

$1.26 -0.12 (-8.70%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.25 -0.01 (-0.40%)

As of 06/26/2025 07:32 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.02 -0.02 (-0.20%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.02 0.00 (0.00%)

As of 06/26/2025 07:51 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time